Drug development
InflaRx develops medicines that block parts of the immune system involved in inflammatory diseases, with a focus on treatments for severe inflammatory and autoimmune conditions.
Customers and revenue model
InflaRx NV
F:IF0
InflaRx NV
F:IF0
Price:
1.101
EUR
4.36%
Market Cap:
€64.8m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently viewed
Price
Company Overview
Business Description
- Sector
- Health Care
- Industry
- Biotechnology
- Headquarters
- Germany DE
- Employees
- 65
- IPO date
- Nov 8, 2017
InflaRx NV is a clinical-stage biopharmaceutical company that develops medicines for inflammatory and autoimmune diseases. Its main approach is to block a part of the immune system called complement, especially the C5a pathway, which can drive harmful inflammation in conditions where the body attacks its own tissues.
The company’s lead products are drug candidates such as vilobelimab, which it has studied in diseases like hidradenitis suppurativa and other severe inflammatory disorders. InflaRx does not sell consumer products; it earns money mainly through research collaborations, licensing arrangements, and any future drug sales or royalties if its medicines reach the market.
Its business is different from a typical drug maker because it is focused on a narrow scientific target and on diseases with limited treatment options. That makes InflaRx more like a specialized research company that tries to turn a specific immune pathway into approved therapies rather than a broad pharmaceutical company with many products.
Continue IF0 Research
Other InflaRx NV listings:
